← TrialMatch
HomeTrials

New Screening and Diagnostic Cut-off Points of PA Patients

This study aims to establish the screening and diagnostic cut-off points for primary aldosteronism patients by a novel small molecule "sandwich method" aldosterone and renin chemiluminescent immunoassay.

Condition(s)Primary Aldosteronism
StatusRecruiting
Study typeObservational
SummaryThis study aims to establish the screening and diagnostic cut-off points for primary aldosteronism patients by a novel small molecule "sandwich method" aldosterone and renin chemiluminescent immunoassay.
Who can participateInclusion Criteria: * 18-75y; * persistent hypertension (BP \>150/100 mm Hg), or drug-resistant hypertension; * newly diagnosed hypertension; * hypertension and spontaneous or diuretic-induced hypokalemia; * hypertension with adrenal incidentaloma; * hypertension and a family history of early-onset hypertension or cerebrovascular accident at a young age (\<40 years); * status as a hypertensive first-degree relative of patients with PA; * patients with hypertension and obstructive sleep apnea. Exclusion Criteria: * age \<18; BMI ≤ 18.0kg/m2 or ≥ 35.0 kg/m2; * a diagnosis of secondary hypertension other than PA; * chronic cardiac dysfunction (NYHA III-IV); * medium and several kidney dysfunction (Ccr\<30ml/min); * liver cirrhosis; * terminal malignant tumor; * recent use of steroids or oral
Ages18 Years to 75 Years
SexAll
Lead sponsorChina National Center for Cardiovascular Diseases
LocationsBeijing, China
Start date2024-01-04
NCT IDNCT06571084
Official listinghttps://clinicaltrials.gov/study/NCT06571084

🔍 Search all trials →